Definium Therapeutics (DFTX) Non-Current Debt (2023 - 2026)

Definium Therapeutics (DFTX) has 4 years of Non-Current Debt data on file, last reported at $40.8 million in Q1 2026.

• Quarterly Non-Current Debt rose 85.03% year-over-year to $40.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.8 million (up 85.03% YoY) and the FY2025 annual result came in at $40.6 million, up 85.68% from the prior year.
• Non-Current Debt held at $40.8 million in Q1 2026 per DFTX's latest filing, from $40.6 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $41.2 million in Q2 2025 and bottomed at $14.1 million in Q3 2023.
• The 4-year median for Non-Current Debt is $24.3 million (2024), against an average of $27.1 million.
• The widest annual swing landed in 2024, when Non-Current Debt surged 54.67%; it then jumped 85.68% in 2025.
• Tracing DFTX's Non-Current Debt over 4 years: stood at $14.1 million in 2023, then surged by 54.67% to $21.9 million in 2024, then jumped by 85.68% to $40.6 million in 2025, then climbed by 0.48% to $40.8 million in 2026.
• Per Business Quant, the three latest DFTX Non-Current Debt figures stand at $40.8 million (Q1 2026), $40.6 million (Q4 2025), and $40.4 million (Q3 2025).

Peer Comparison